why choose us

First received: October 02, 2023

Clinical Trial: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Low Grade Serous Ovarian Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Canc

Brief Summary: This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Read more